size of pterygium signs and symptoms of pterygium side effects of intralesional injection of bevacizumab in primary pterygium bevacizumab,
Conditions
Interventions
all of the patients received three doses intralesional injection of 2 mg (1 mg/0.04 mL) of bevacizumab at 0,
4 wks,
8 wks,In the control group,
all of the patients received a combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04% for 6 months
Experimental Drug,Active Comparator Drug
Bevacizumab group,Topical Antazoline HCl 0.05% and Tetrahydrozoline HCl 0.04% group
In the treatment group,
Sponsors
Research Affairs, Faculty of Medicine, Khon Kaen University
Faculty of Medicine,
Srinagarind Hospital
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: Primary pterygium patients older than 20 years
Exclusion criteria
Exclusion criteria: Ptergium involve visual axis, Recurrent pterygium, Pterygium with symblepharon, Patients with history of ocular chemical or thermal burn, Pregnant and breastfeeding female, Patients with history of stroke or thromboembolism disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area of pterygium 0 wk, 4 wk, 24 wk mm square/ImageJ program | — |
Secondary
| Measure | Time frame |
|---|---|
| symptoms(eye irritation, photophobia, epiphora, redness, amount of discharge, and blurred vision) 0 wk, 4 wk, 24 wk subjectively graded by the patients on an 11-point scale [range, 0 (low) to 10 (high)] | — |
Countries
Thailand
Contacts
Public ContactOrapin Anutarapongpan
Faculty of Medicine, Khon Kaen University
Outcome results
None listed